Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTP-850
- Development stage
- Discontinued
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Intramuscular
01
Overview
VTP-850 is a next-generation prostate cancer immunotherapeutic designed as a heterologous prime-boost vaccine consisting of two nonreplicating viral-vectored components: ChAdOx1-PCAQ (adenoviral vector) and MVA-PCAQ (modified vaccinia virus Ankara vector). Both vectors encode four prostate cancer-associated antigens—prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six transmembrane epithelial antigen of prostate 1 (STEAP1), and 5T4, an oncofetal antigen. The vaccine aims to stimulate a broad T cell immune response targeting these antigens to kill tumor cells and prevent progression to metastatic disease in men with biochemical recurrence after definitive local therapy for prostate cancer. Preclinical studies demonstrated strong immunogenicity with robust T cell responses, particularly against PSA. Clinical development includes Phase 1/2 trials evaluating safety, immunogenicity, and PSA response rate in men with rising PSA levels post-primary treatment. VTP-850 is investigational and not yet approved by regulatory authorities.
- Other names
- ChAdOx1-PCAQ and MVA-PCAQ (components of VTP-850)
02
Targets
TPBG (Trophoblast glycoprotein)PSA (Puromycin-sensitive aminopeptidase)PAP (Prostatic acid phosphatase)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)
Beyond the preview
Go deeper on VTP-850.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTP-850.